Video

Matthew Galsky Gives an Overview of Bladder Cancer

Author(s):

Matthew Galsky, M.D.

Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.

Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.

Galsky gives an overview of each bladder cancer type, starting with non-muscle invasive bladder cancer, and talks about treatment options and likelihood of cure or recurrence.

Related Videos
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Image of man with grey hair.
Image of man with black hair.
Image of doctor with grey hair.
Image of doctor with black hair.
Related Content
Cretostimogene shows best-in-class durability of response for BCG-unresponsive NMIBC with CIS: © pikovit - stock.adobe.com.
March 24th 2025

Cretostimogene Has Durable Response in BCG-Unresponsive Bladder Cancer

Ryan Scott
Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Jelmyto demonstrates long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months. © - stock.adobe.com
March 15th 2025

Jelmyto Maintains Effectiveness Over Time in Bladder Cancer Subtype

Spencer Feldman
Jelmyto demonstrated long-term efficacy in low-grade upper tract urothelial carcinoma, with most maintaining complete response after several months.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Illustration of bladder.
March 13th 2025

Antihistamines Associated With Bladder Cancer Survival, Progression Improvements

Alex Biese
Antihistamines are associated with improvement for patients with metastatic urothelial carcinoma receiving Tecentriq.
Following the BCG shortage, the first patient with bladder cancer has been dosed with rBCG in the U.S. © freshidea - stock.adobe.com
March 13th 2025

First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer

Spencer Feldman
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant Bacillus Calmette-Guérin in the U.S.